Skip to content
1st Counsel – Lifestyle
Author:
Ensysce Biosciences
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
September 15, 2026
Ensysce Biosciences’ Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
September 14, 2026
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
September 2, 2026
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
August 31, 2026
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
August 6, 2026
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
July 14, 2026
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
June 26, 2026
Ensysce Biosciences Reports First Quarter 2026 Financial Results
May 15, 2026
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
May 12, 2026
1
2
Next Page
→